Xarelto Lawsuit Plaintiffs Gain Support From BMJ Study Indicating Possible Twofold Increase In GI Bleed Risk

March 24, 2016 – – BloodThinnerHelp.com reports on the results of several medical studies which potentially link the use of new-generation blood thinner Xarelto to an elevated risk for sudden and dangerous bleeding episodes, including but not limited to spontaneous vitreous hemorrhages, (or eye bleeds), brain bleeds, stomach bleeds, and internal gastrointestinal bleeds. The study results, though alarming, could lend assistance to the thousands of plaintiffs currently involved in lawsuits filed against Xarelto’s manufacturers Janssen and Bayer.

A study which was published in JAMA Ophthalmology on June 25th of 2015 seems to expose a link between patient use of rivaroxaban (Xarelto’s generic form) and an increased risk for the development of hemorrhages within the eyes. Physicians noting this indicated that they had discovered that, “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.” This new find could be critical information for patients looking to switch to Xarelto from traditional blood thinners.

The U.S. Food and Drug Administration approved Xarelto in 2011, though this approval is currently under investigation pending some potentially invalid clinical trial results due to a recalled testing device. Since this time, however, the FDA has given Xarelto two “black box” warnings. Black box warnings are the most severe warnings products are able to receive from the agency before they are fully removed from the market.

Another notable study surrounding the anticoagulant has linked potential health problems to Xarelto use. This study was published in an April 2015 issue of BMJ (formerly British Medical Journal). The results from this study indicated that Xarelto (rivaroxaban) use might as much as double a patient’s risk of developing a gastrointestinal bleed in comparison to patients taking traditional blood thinner warfarin. Upon completion of this study researchers noted, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”

Attorney Joseph Osborne understands how concerning these study results could be for patients currently using Xarelto. He is working to assist those who may have suffered from adverse events which they believe were caused by their use of the blood thinner. These patients should be entitled to the opportunity to fully investigate their legal rights in the matter. Those affected may qualify for significant compensation gained through legal action. To better assist those wishing to pursue justice, Attorney Osborne is currently offering free legal consultations for qualified parties.

To request additional information, or to ask questions regarding Xarelto bleeding lawsuits, please contact attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008877